Ambrisentan Moving Closer to Approval

Happily tracking the progress of Gilead Sciences, Inc. (NASDAQ: GILD) Ambrisentan asset; for the treatment of pulmonary arterial hypertension. Gilead’s recent announcement that the FDA has accepted for filing and granted a priority review for the NDA is exciting news for the Colorado bio-scape. This approval may result in an accelerated review with an expectation of a 18 June 2007 review date. Recall that Gilead recently acquired Westminster, CO based Myogen for $2.5B.